ALTHOUGH basic mechanisms of bronchial hyper-responsiveness (BHR) are
still incompletely understood, inflammation of airways is likely to pl
ay a fundamental role in modulating BHR in patients with asthma. The i
nvolvement of several inflammatory cells (eosinophils, mast cells, lym
phocytes, neutrophils, macrophages and platelets) and of bioactive med
iators secreted by these cells in the pathogenesis of asthma is well d
ocumented. Sodium cromoglycate and nedocromil sodium are two pharmacol
ogical agents which have anti-allergic and anti-inflammatory propertie
s. Their clinical effectiveness in mild to moderate asthma, and the ca
pacity to reduce BHR under different natural and experimental conditio
ns, make them valuable drugs for maintenance therapy in patients with
asthma.